Market Overview

Why NantKwest's Stock Is Trading Higher Today

Share:
Why NantKwest's Stock Is Trading Higher Today

NantKwest (NASDAQ: NK) shares are trading higher on Thursday after the company announced it has received authorization from the FDA to begin a Phase I clinical trial of hAd5-COVID-19, the company's COVID-19 vaccine candidate.

NantKwest is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected.

NantKwest shares traded up 9.83% to $9.94 on Thursday. The stock has a 52-week high of $15.70 and a 52-week low of $1.05.

 

Related Articles (NK)

View Comments and Join the Discussion!

Posted-In: why it's movingNews FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com